A Landscape of Artificial Intelligence (AI) In Pharmaceutical R&D

Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

Antibiotic resistance


Vaccine Nationalism, CDMO expansion, AMR and Dual sourcing predicted in 2021 According to New CPhI Report

   by Abdul Khalifeh    201
Vaccine Nationalism, CDMO expansion, AMR and Dual sourcing predicted in 2021 According to New CPhI Report

A new report from CPhI explores the potential implications in 2021 of impending vaccine approvals, a new administration in the White House and a return to dual supply chain strategies.

The report – which summarises expert analysis into 12 key findings – foresees a particularly positive outlook for the pharma manufacturing supply chain, as a result of the demand for increased second source contingencies, alongside the huge scale-up of vaccine capacity currently underway. A consequence of which is likely to encourage expansion across the contract services sector for all product classes and therapy areas.

How To Be Ready For Future Pandemics?

   by Andrii Buvailo    926
How To Be Ready For Future Pandemics?

What do antibiotic-resistant bacteria (“superbugs”) and coronaviruses have in common? They both can kill lots of people globally, and they both have been commercially unattractive targets for the pharma business for too long.

 

FDA Analysis of Antibiotic Development - with Hubris!

   by David Shlaes    520
FDA Analysis of Antibiotic Development - with Hubris!
(This post originally appeared on David Shlaes's personal blog)
 
The US FDA just published an analysis of antibiotic development looking back over the last 40 years. The paper was accompanied by an editorial by Rex and Outterson. These papers are well worth reading and I highly recommend them for everyone whether they are familiar with antibiotic development or not. I must say that the hubris of the FDA analysis is astounding (see below).